Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ENTXBullishCorporate Developmentsnews

High materiality8/10

Entera Bio gains FDA nod-path for EB613; NDA potential by 2028

Jun 23, 2026, 8:54 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive regulatory alignment reduces execution risk and sets NDA trajectory; financing news adds liquidity and investor interest. Historically, micro-cap biotech milestones tied to FDA progress and topline data can trigger meaningful near-term upside, though execution risk remains.

AI summary

What happened, with direct paths to the underlying reporting

FDA feedback accepted Entera Bio's registrational Phase 3 design for EB613, a 750-patient, single randomized trial with 12-month total hip BMD as primary endpoint, supporting an NDA in 2028. ENDO 2026 data showed oral EB613 PK/PD parity with Forteo, reinforcing a path to broader patient access and potential market impact.

FDA provides positive EB613 Phase 3 feedback. 750-patient trial; 12-month hip BMD endpoint.
FDA alignment supports NDA submission; topline results expected in 2H 2028.
Endo 2026 PK/PD data shows parity to Forteo for single-tablet EB613.
EB613 could become first oral anabolic osteoporosis treatment; injection hurdle addressed.
ENTX market cap under $75M pre-news; BVF-OPKO partnerships broaden catalyst runway.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Entera Bio gains FDA nod-path for EB613; NDA potential by 2028

Entera Bio secures financing to extend runway and advance EB613 toward FDA

Entera Bio Posts Losses, Suffering Significant Share Price Drop